Pilot Trial of Inhaled Molgramostim in Nontuberculous Mycobacterial (NTM) Infection
Status:
Completed
Trial end date:
2020-01-13
Target enrollment:
Participant gender:
Summary
The trial is an open-label, non-controlled, multicenter, pilot clinical trial of inhaled
molgramostim (recombinant human Granulocyte-Macrophage Colony Stimulating Factor; rhGM-CSF)
in subjects with persistent pulmonary Nontuberculous Mycobacterial (NTM) infection. Subject
will be treated for 24-weeks with inhaled molgramostim and will be followed up for 12-weeks
after end of treatment. The primary aim of the trial is to investigate the efficacy of
inhaled molgramostim on NTM sputum culture conversion to negative.